Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

Phase 3 Completed 100 enrolled AO GENERIUM

RandomizedParallel-groupOpen-labelTreatment

Summary

It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.

Timeline

Start: 2020-06-01
Primary completion: 2020-07-20
Completion: 2020-07-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dornase alfa	Protein / enzyme biologic	2.5 mg	Inhaled

Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

Summary

Timeline

Drugs

Indications